[Biological therapy as an alternative treatment for cytokine release syndrome in patients with COVID-19].
作者信息
Solis Cartas Urbano
机构信息
Universidad Nacional de Chimborazo; Escuela Superior Politécnica de Chimborazo, Riobamba, Chimborazo, Ecuador.
出版信息
Rev Colomb Reumatol. 2022 Jan-Mar;29(1):74-75. doi: 10.1016/j.rcreu.2020.06.007. Epub 2020 Jul 19.
Abstract
摘要
相似文献
1
[Biological therapy as an alternative treatment for cytokine release syndrome in patients with COVID-19].
Rev Colomb Reumatol. 2022 Jan-Mar;29(1):74-75. doi: 10.1016/j.rcreu.2020.06.007. Epub 2020 Jul 19.
2
Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome.
Eur J Case Rep Intern Med. 2020 Apr 22;7(5):001675. doi: 10.12890/2020_001675. eCollection 2020.
3
Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality.
Int Rev Immunol. 2022;41(2):217-230. doi: 10.1080/08830185.2021.1884248. Epub 2021 Feb 22.
4
Success of the Cytokine Absorption Therapies in COVID-19 Patients Diagnosed with Cytokine Release Syndrome.
J Coll Physicians Surg Pak. 2022 Apr;32(4):451-454. doi: 10.29271/jcpsp.2022.04.451.
5
Impact of Tocilizumab on Clinical Outcomes in COVID-19-Associated Cytokine Release Syndrome: A Single-Center Experience.
J Pharm Pract. 2023 Apr;36(2):213-220. doi: 10.1177/08971900211028208. Epub 2021 Jul 7.
6
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
7
High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.
J Autoimmun. 2020 Dec;115:102537. doi: 10.1016/j.jaut.2020.102537. Epub 2020 Aug 20.
8
Prolonged NHE Activation may be both Cause and Outcome of Cytokine Release Syndrome in COVID-19.
Curr Pharm Des. 2022;28(22):1815-1822. doi: 10.2174/1381612828666220713121741.
9
HIV and Associated Indicators of COVID-19 Cytokine Release Syndrome: A Meta-Analysis and Meta-Regression.
Cureus. 2023 Feb 6;15(2):e34688. doi: 10.7759/cureus.34688. eCollection 2023 Feb.
10
Potential Therapeutic Role of Mesenchymal-Derived Stem Cells as an Alternative Therapy to Combat COVID-19 through Cytokines Storm.
Cells. 2022 Aug 29;11(17):2686. doi: 10.3390/cells11172686.
本文引用的文献
1
[Therapeutic Options for the Management of Severe COVID-19: A Rheumatology Perspective].
Reumatol Clin. 2021 Oct;17(8):431-436. doi: 10.1016/j.reuma.2020.05.002. Epub 2020 May 16.
2
Tocilizumab treatment in COVID-19: A single center experience.
J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15.
3
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
4
Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.
Blood. 2016 Jul 7;128(1):60-71. doi: 10.1182/blood-2016-02-700013. Epub 2016 May 24.
5
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.
Crit Care Med. 2016 Feb;44(2):275-81. doi: 10.1097/CCM.0000000000001402.
Zotero 插件